(64)Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients.

Autor: Kurihara H; Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan., Hamada A; Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan., Yoshida M; Department of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan., Shimma S; Department of Clinical Pharmacology Group for Translational Research Support Core, National Cancer Center Research Institute, Tokyo, Japan., Hashimoto J; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yonemori K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Tani H; Department of Diagnostic Radiology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan., Miyakita Y; Department of Neurosurgery, National Cancer Center Hospital, Tokyo, Japan., Kanayama Y; RIKEN Center for Life Science Technologies, Hyogo, Japan., Wada Y; RIKEN Center for Life Science Technologies, Hyogo, Japan., Kodaira M; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yunokawa M; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Yamamoto H; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Shimizu C; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Takahashi K; RIKEN Center for Life Science Technologies, Hyogo, Japan., Watanabe Y; RIKEN Center for Life Science Technologies, Hyogo, Japan., Fujiwara Y; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan., Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jazyk: angličtina
Zdroj: EJNMMI research [EJNMMI Res] 2015 Mar 12; Vol. 5, pp. 8. Date of Electronic Publication: 2015 Mar 12 (Print Publication: 2015).
DOI: 10.1186/s13550-015-0082-6
Abstrakt: Background: The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab.
Methods: PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of (64)Cu-DOTA-trastuzumab.
Results: Metastatic brain lesions could be visualized by (64)Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS.
Conclusions: Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer.
Trial Registration: UMIN000004170.
Databáze: MEDLINE
Externí odkaz: